共 54 条
[1]
Woldeamanuel YW(2017)Migraine affects 1 in 10 people worldwide featuring recent rise: a systematic review and meta-analysis of community-based studies involving 6 million participants J Neurol Sci 372 307-315
[2]
Cowan RP(2007)Migraine prevalence, disease burden, and the need for preventive therapy Neurology 68 343-349
[3]
Lipton RB(2020)Identifying barriers to care-seeking, diagnosis, and preventive medication among those with migraine: results of the OVERCOME study [abstract] Headache 60 127-128
[4]
Bigal ME(2020)Characteristics of individuals with migraine who are eligible for novel CGRP monoclonal antibodies: results of the OVERCOME study [abstract] Headache 60 126-127
[5]
Diamond M(2014)Systematic review of migraine prophylaxis adherence and persistence J Manag Care Pharm 20 22-33
[6]
Freitag F(2008)Prophylaxis of migraine: general principles and patient acceptance Neuropsychiatr Dis Treat 4 1155-1167
[7]
Reed ML(2018)Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial JAMA Neurol 75 1080-1088
[8]
Stewart WF(2018)Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial Cephalalgia 38 1442-1454
[9]
Ashina S(2018)Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study Neurology 19 e2211-e2221
[10]
Nicholson RA(2020)Rapid onset of effect of galcanezumab for the prevention of episodic migraine: analysis of the EVOLVE studies Headache 60 348-359